REFERENCES
- FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993; 122: 1–9.
- Gilligan PH. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 1991; 4: 35–51.
- Burns JL, Emerson J, Stapp JR et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998; 27: 158–163.
- Ratjen F, airing G, Nikolaizik WH. Inhaled tobramycin eradicates early P. aeruginosa colonization in patients with cystic fibrosis. Lancet 2001; 358: 983–4.
- Taccetti G, Repetto T, Procopio E, Farina S, Campana S. Early Pseudomonas aeruginosa colonisation in cystic fibro-sis patients. Lancet 2002; 359: 625–6.
- Regelmann W, Eliott G, Warwick W, Clawson C. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990; 141: 914–921.
- Smith A, Doershuk C, Goldmann D, Gore E, Hilman B. Comparison of a beta -lactam alone versus beta-lactam and aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 1999; 134: 413–421.
- Grimwood K, To M, Rabin H, Woods D. Inhibition of Pseudomonas aeruginosa exoenzyme expression by sub-hinibitory antibiotic concentration. Antimicrob Agents Chemother 1989; 33: 41–47.
- Gilbert DNJr Moellering RC, Sande MA. eds. Guida Sanford alla terapia antimicrobica. 31st ed. Aventis 2001.
- Abramowicz M. ed. Guida alla terapia antimicrobica. Edizione aggiornata 2002. Ed CIS.
- Döring G, Conway SP, Heijerman HGM, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000; 16: 749–767.
- Shawn DA, Ferris W, Henry DA, Speert DP, MacDonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burk-holderia cepacia. Am J Respir Crit Care Med 2000; 161: 1206–1212.
- Burns JL, Saiman L, Whittiet S. Continuing update on the role of the clinical microbiology laboratory. Twelfth Annual North American Cystic Fibrosis Conference. 1998
- White RL, Burgess DS, Manduru M, Bosso JA. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E-test. Antimicrob Agents Chemother 1996; 40 (8): 1914–1918.
- Marshall B, Samuelson W. Basic therapies in cystic fibrosis: does standard therapy work? Clin Chest Med 1998; 19: 487–504.
- Cantin A, Woods D. Protection by antibiotics against myeloperoxidase-dependent cytotoxicity to lung epithelial cells in vitro. J Clin Invest 1993; 91: 38–45.
- Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340: 23–30.
- Labro MT. Anti-inflammatory activity of macrolides: a new therapeutic potential? J Antimicrob Chemother 1998; 41: 37–46.
- Saiman L, Mehar F, Niu WW et al. Antibiotic suscepti-bility of multiply resistant Pseudomonas aeruginosa isolates from CF patients, including transplant candidates. Clin Infect Dis 1996; 23: 532–537.
- Saiman L, Chen Y, San Gabriel P, Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxi-dans isolated from patients with cystic fibrosis. J Antimicrob Chemother 2002; 46 (4): 1105–1107.